Novel immunotherapeutic approaches for treatment of infertility

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 1449-1459

  Abdolmohammadi Vahid, Samaneh ^a,b   Danaii, Shahla ^c   Hamdi, Kobra ^d   Jadidi Niaragh, Farhad ^a,b,e   Ahmadi, Majid ^a,b   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Department of Medicinal Plants ACECR (East Azerbaijan Branch)   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunotherapy; Infertility; Miscarriage

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTRALIPID; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

CELL THERAPY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO FERTILIZATION; INFERTILITY; INFERTILITY THERAPY; PATERNAL LYMPHOCYTE IMMUNIZATION; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SPONTANEOUS ABORTION; ANIMAL; DRUG EFFECTS; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PREGNANCY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFERTILITY; PREGNANCY; TREATMENT OUTCOME;

EID: 85001070130     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.10.062     Document Type: Review

References (158)

1. [1] Inhorn, M.C., Patrizio, P., Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum. Reprod. Update, 2015, 411–426.
2. [2] Sagili, H., Divers, M., Modern management of miscarriage. Obstet. Gynecol. 9:2 (2007), 102–108.
3. [3] Agenor, A., Bhattacharya, S., Infertility and miscarriage: common pathways in manifestation and management. Women's Health 11:4 (2015), 527–541.
4. [4] Bates, S.M., Consultative hematology: the pregnant patient pregnancy loss. ASH Educ. Program Book 2010:1 (2010), 166–172.
5. [5] Li, T., Tuckerman, E., Laird, S., Endometrial factors in recurrent miscarriage. Hum. Reprod. Update 8:1 (2002), 43–52.
6. [6] Comba, C., Bastu, E., Dural, O., Yasa, C., Keskin, G., Ozsurmeli, M., Buyru, F., Serdaroglu, H., Role of inflammatory mediators in patients with recurrent pregnancy loss. Fertil. Steril., 104(6), 2015 (1467-1474e1).
7. [7] Bulletti, C., Flamigni, C., Giacomucci, E., Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum. Reprod. Update 2:2 (1996), 118–136.
8. [8] Patriarca, A., Piccioni, V., Gigante, V., Benedetto, C., The use of intravenous immunoglobulin in sine causa or alloimmune recurrent spontaneous abortion (RSA). Panminerva Med. 42:3 (2000), 193–195.
9. [9] Omwandho, C.A., Tinneberg, H.R., Tumbo-Oeri, A.G., Roberts, T.K., Falconer, J., Recurrent pregnancy losses and the role of immunotherapy. Arch. Gynecol. Obstet. 264:1 (2000), 3–12.
10. [10] Christiansen, O.B., Andersen, A.-M.N., Bosch, E., Daya, S., Delves, P.J., Hviid, T.V., Kutteh, W.H., Laird, S.M., Li, T.-C., van der Ven, K., Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil. Steril. 83:4 (2005), 821–839.
11. [11] Yang, H., Qiu, L., Di, W., Zhao, A., Chen, G., Hu, K., Lin, Q., Proportional change of CD4+ CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients. Fertil. Steril. 92:1 (2009), 301–305.
12. [12] Nakagawa, K., Kwak-Kim, J., Ota, K., Kuroda, K., Hisano, M., Sugiyama, R., Yamaguchi, K., Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. Am. J. Reprod. Immunol. 73:4 (2015), 353–361.
13. [13] Shreeve, N., Sadek, K., Intralipid therapy for recurrent implantation failure: new hope or false dawn?. J. Reprod. Immunol. 93:1 (2012), 38–40.
14. [14] Coulam, C.B., Acacio, B., Does immunotherapy for treatment of reproductive failure enhance live births?. Am. J. Reprod. Immunol. 67:4 (2012), 296–304.
15. [15] Toth, B., Jeschke, U., Rogenhofer, N., Scholz, C., Würfel, W., Thaler, C.J., Makrigiannakis, A., Recurrent miscarriage: current concepts in diagnosis and treatment. J. Reprod. Immunol. 85:1 (2010), 25–32.
16. [16] Forges, T., Monnier-Barbarino, P., Guillet-May, F., Faure, G.C., Béné, M.-C., Corticosteroids in patients with antiovarian antibodies undergoing in vitro fertilization: a prospective pilot study. Eur. J. Clin. Pharmacol. 62:9 (2006), 699–705.
17. [17] Hasegawa, I., Yamanoto, Y., Suzuki, M., Murakawa, H., Kurabayashi, T., Takakuwa, K., Tanaka, K., Prednisolone plus low-dose aspirin improves the implantation rate in women with autoimmune conditions who are undergoing in vitro fertilization. Fertil. Steril. 70:6 (1998), 1044–1048.
18. [18] Tang, A.-W., Alfirevic, Z., Turner, M.A., Drury, J., Quenby, S., Prednisolone trial: study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium. Trials, 10(1), 2009, 1.
19. [19] Addison, R., Maguire, D., Mortimer, R., Roberts, M., Cannell, G., Pathway and kinetics of prednisolone metabolism in the human placenta. J. Steroid Biochem. Mol. Biol. 44:3 (1993), 315–320.
20. [20] Dan, S., Wei, W., Yichao, S., Hongbo, C., Shenmin, Y., Jiaxiong, W., Hong, L., Effect of prednisolone administration on patients with unexplained recurrent miscarriage and in routine intracytoplasmic sperm injection: a meta-analysis. Am. J. Reprod. Immunol. 74:1 (2015), 89–97.
21. [21] Makhseed, M., Raghupathy, R., Azizieh, F., Omu, A., Al-Shamali, E., Ashkanani, L., Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum. Reprod. 16:10 (2001), 2219–2226.
22. [22] Xu, B., Makris, A., Thornton, C., Hennessy, A., Glucocorticoids inhibit placental cytokines from cultured normal and preeclamptic placental explants. Placenta 26:8 (2005), 654–660.
23. [23] Kwak-Kim, J., Gilman-Sachs, A., Kim, C., T helper 1 and 2 immune responses in relationship to pregnancy, nonpregnancy, recurrent spontaneous abortions and infertility of repeated implantation failures. Immunology of Gametes and Embryo Implantation, 2005, Karger Publishers, 64–79.
24. [24] Lash, G.E., Bulmer, J.N., Innes, B.A., Drury, J.A., Robson, S.C., Quenby, S., Prednisolone treatment reduces endometrial spiral artery development in women with recurrent miscarriage. Angiogenesis 14:4 (2011), 523–532.
25. [25] Quenby, S., Kalumbi, C., Bates, M., Farquharson, R., Vince, G., Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Fertil. Steril. 84:4 (2005), 980–984.
26. [26] Gomaa, M.F., Elkholy, A.G., El-Said, M.M., Abdel-Salam, N.E., Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch. Gynecol. Obstet. 290:4 (2014), 757–762.
27. [27] Tang, A.-W., Alfirevic, Z., Turner, M.A., Drury, J.A., Small, R., Quenby, S., A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum. Reprod. 28:7 (2013), 1743–1752.
28. [28] Fawzy, M., El-Refaeey, A.-A.A., Does combined prednisolone and low molecular weight heparin have a role in unexplained implantation failure?. Arch. Gynecol. Obstet. 289:3 (2014), 677–680.
29. [29] Bramham, K., Thomas, M., Nelson-Piercy, C., Khamashta, M., Hunt, B.J., First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117:25 (2011), 6948–6951.
30. [30] Taniguchi, F., Results of prednisolone given to improve the outcome of in vitro fertilization-embryo transfer in women with antinuclear antibodies. J. Reprod. Med. 50:6 (2005), 383–388.
31. [31] Ando, T., Suganuma, N., Furuhashi, M., Asada, Y., Kondo, I., Tomoda, Y., Successful glucocorticoid treatment for patients with abnormal autoimmunity on in vitro fertilization and embryo transfer. Assist. Reprod. Genet. 13:10 (1996), 776–781.
32. [32] Barreiro, C., Martínez-Castro, M., Trends in the biosynthesis and production of the immunosuppressant tacrolimus (FK506). Appl. Microbiol. Biotechnol. 98:2 (2014), 497–507.
33. [33] Kino, T., Goto, T., Discovery of FK-506 and update. Ann. N. Y. Acad. Sci. 685:1 (1993), 13–21.
34. [34] Wallemacq, P.E., Reding, R., FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin. Chem. 39:11 (1993), 2219–2228.
35. [35] Goring, S.M., Levy, A.R., Ghement, I., Kalsekar, A., Eyawo, O., L'Italien, G.J., Kasiske, B., A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr. Med. Res. Opin. 30:8 (2014), 1473–1487.
36. [36] Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., Goto, T., Okuhara, M., Kohsaka, M., Aoki, H., FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 40:9 (1987), 1256–1265.
37. [37] Ram, R., Gafter-Gvili, A., Yeshurun, M., Paul, M., Raanani, P., Shpilberg, O., Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant. 43:8 (2009), 643–653.
38. [38] Ramiro, S., Gaujoux-Viala, C., Nam, J.L., Smolen, J.S., Buch, M., Gossec, L., Van Der Heijde, D., Winthrop, K., Landewé, R., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis. 73:3 (2014), 529–535.
39. [39] Kwak-Kim, J., Chung-Bang, H., Ng, S., Ntrivalas, E., Mangubat, C., Beaman, K., Beer, A., Gilman-Sachs, A., Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum. Reprod. 18:4 (2003), 767–773.
40. [40] Liu, J., Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., Schreiber, S.L., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:4 (1991), 807–815.
41. [41] O'Keefe, S.J., Tamura, J.I., Kincaid, R.L., Tocci, M.J., O'Neill, E.A., FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature, 1992, 692–694.
42. [42] Emmel, E.A., Verweij, C., Durand, D.B., Higgins, K., Lacy, E., Crabtree, G.R., Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246 (1989), 1617–1620.
43. [43] Liu, J., Sakane, T., Tsunematsu, T., The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6. Int. Arch. Allergy Immunol. 98:4 (1992), 293–298.
44. [44] Nelson, P., Akselband, Y., Kawamura, A., Su, M., Tung, R., Rich, D., Kishore, V., Rosborough, S., DeCenzo, M., Livingston, D., Immunosuppressive activity of [MeBm2t] 1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity. J. Immunol. 150:6 (1993), 2139–2147.
45. [45] Zhou, W.-H., Du, M.-R., Dong, L., Zhu, X.-Y., Yang, J.-Y., He, Y.-Y., Li, D.-J., Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway. Hum. Reprod. 22:10 (2007), 2743–2750.
46. [46] Alvarez-Arroyo, M.V., Yagüe, S., Wenger, R.M., Pereira, D.S., Jiménez, S., González-Pacheco, F.R., Castilla, M.A., Deudero, J.J.P., Caramelo, C., Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells role of vascular endothelial growth factor. Circ. Res. 91:3 (2002), 202–209.
47. [47] Yang, F., Robotham, J.M., Grise, H., Frausto, S., Madan, V., Zayas, M., Bartenschlager, R., Robinson, M., Greenstein, A.E., Nag, A., A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog., 6(9), 2010, e1001118.
48. [48] Wu, X., Nguyen, B.-C., Dziunycz, P., Chang, S., Brooks, Y., Lefort, K., Hofbauer, G.F., Dotto, G.P., Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 465:7296 (2010), 368–372.
49. [49] Periyasamy, S., Hinds, T., Shemshedini, L., Shou, W., Sanchez, E.R., FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 29:11 (2010), 1691–1701.
50. [50] Du, M.-R., Dong, L., Zhou, W.-H., Yan, F.-T., Li, D.-J., Cyclosporin a improves pregnancy outcome by promoting functions of trophoblasts and inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in the mouse. Biol. Reprod. 76:5 (2007), 906–914.
51. [51] Piao, H.-L., Wang, S.-C., Tao, Y., Zhu, R., Sun, C., Fu, Q., Du, M.-R., Li, D.-J., Cyclosporine A enhances Th2 bias at the maternal-fetal interface in early human pregnancy with aid of the interaction between maternal and fetal cells. PLoS One, 7(9), 2012, e45275.
52. [52] Wasowska, B.A., Zheng, X., Strom, T.B., Kupiec- Weglinski, J.W., Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associatedcytokines/chemokines in sensitized cardiac graft recipients. Transplantation 71:8 (2001), 1179–1183.
53. [53] Sauma, D., Fierro, A., Mora, J., Lennon-Duménil, A.M., Bono, M.R., Rosemblatt, M., Morales, J., Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect. Transplant Proc, 2003, Elsevier, 2515–2517.
54. [54] Chen, T., Guo, J., Yang, M., Han, C., Zhang, M., Chen, W., Liu, Q., Wang, J., Cao, X., Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 103:2 (2004), 413–421.
55. [55] Poggi, A., Zocchi, M.R., Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun. Rev. 4:8 (2005), 532–536.
56. [56] Du, M., Zhou, W., Piao, H., Li, M., Tang, C., Li, D., Cyclosporin A promotes crosstalk between human cytotrophoblast and decidual stromal cell through up-regulating CXCL12/CXCR4 interaction. Hum. Reprod., 2012, 1955–1965.
57. [57] Du, M.-R., Zhou, W.-H., Dong, L., Zhu, X.-Y., He, Y.-Y., Yang, J.-Y., Li, D.-J., Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways. Biol. Reprod. 78:6 (2008), 1102–1110.
58. [58] Du, M.-R., Zhou, W.-H., Yan, F.-T., Zhu, X.-Y., He, Y.-Y., Yang, J.-Y., Li, D.-J., Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. Hum. Reprod. 22:9 (2007), 2528–2537.
59. [59] Tang, C.-L., Zhao, H.-B., Li, M.-Q., Du, M.-R., Meng, Y.-H., Li, D.-J., Focal adhesion kinase signaling is necessary for the Cyclosporin A-enhanced migration and invasion of human trophoblast cells. Placenta 33:9 (2012), 704–711.
60. [60] Sketris, I., Yatscoff, R., Keown, P., Canafax, D.M., First, M.R., Holt, D.W., Schroeder, T.J., Wright, M., Optimizing the use of cyclosporine in renal transplantation. Clin. Biochem. (CLB) 28:3 (1995), 195–211.
61. [61] Germano, V., Picchianti, D.A., Ferlito, C., Podesta, E., Salemi, S., Migliore, A., D'Amelio, R., Lagana, B., Cyclosporine A in the long-term management of systemic lupus erythematosus. J. Biol. Regul. Homeost. Agents 25:3 (2010), 397–403.
62. [62] Hetland, M.L., Modern treatment strategies in rheumatoid arthritis. Dan. Med. Bull., 58(11), 2011, B4320.
63. [63] Fu, J., Analysis of the use of cyclosporin A to treat refractory immune recurrent spontaneous abortion. Clin. Exp. Obstet. Gynecol. 42:6 (2014), 739–742.
64. [64] Imbach, P., d'Apuzzo, V., Hirt, A., Rossi, E., Vest, M., Barandun, S., Baumgartner, C., Morell, A., Schöni, M., Wagner, H., High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 317:8232 (1981), 1228–1231.
65. [65] Luke, P.P., Scantlebury, V.P., Jordan, M.L., Vivas, C.A., Hakala, T.R., Jain, A., Somani, A., Fedorek, S., Randhawa, P., Shapiro, R., Reversal of steroid-and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72:3 (2001), 419–422.
66. [66] Branch, D.W., Porter, T.F., Paidas, M.J., Belfort, M.A., Gonik, B., Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J. Allergy Clin. Immunol. 108:4 (2001), S133–S138.
67. [67] Sokos, D.R., Berger, M., Lazarus, H.M., Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 8:3 (2002), 117–130.
68. [68] Casadei, D.H., Rial, M.d.C., Opelz, G., Golberg, J.C., Argento, J.A., Greco, G., Guardia, O.E., Haas, E., Raimondi, E.H., A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71:1 (2001), 53–58.
69. [69] Virro, M.R., Winger, E.E., Reed, J.L., Intravenous immunoglobulin for repeated IVF failure and unexplained infertility. Am. J. Reprod. Immunol. 68:3 (2012), 218–225.
70. [70] Mahjabeen, W., Kafeel, S., Alam, S., Bibi, R., Immunoglobulin therapy in recurrent pregnancy loss. J. Islamabad Med. Dent. College (JIMDC) 2:4 (2013), 64–68.
71. [71] Morikawa, M., Yamada, H., Kato, E.H., Shimada, S., Kishida, T., Yamada, T., Fujimoto, S., Kobashi, G., Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: down-Regulation of NK cell activity and subsets. Am. J. Reprod. Immunol. 46:6 (2001), 399–404.
72. [72] Shimada, S., Takeda, M., Nishihira, J., Kaneuchi, M., Sakuragi, N., Minakami, H., Yamada, H., A high dose of intravenous immunoglobulin increases CD94 expression on natural killer cells in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 62:5 (2009), 301–307.
73. [73] Kwak, J., Kwak, F., Ainbinder, S., Ruiz, A., Beer, A., Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 35:4 (1996), 363–369.
74. [74] Ruiz, J.E., Kwak, J.Y., Baum, L., Gilman‐Sachs, A., Beaman, K.D., Kim, Y.B., Beer, A.E., Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 35:4 (1996), 370–375.
75. [75] Wong, L.F., Porter, T.F., Scott, J.R., Immunotherapy for Recurrent Miscarriage. 2014, The Cochrane Library.
76. [76] Clark, D.A., Wong, K., Banwatt, D., Chen, Z., Liu, J., Lee, L., Gorczynski, R.M., Blajchman, M.A., CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 25:2-3 (2008), 67–72.
77. [77] Caspi, R.R., Expanding tregs with IVIg. Blood 111:2 (2008), 481–482.
78. [78] Heilmann, L., Schorsch, M., Hahn, T., Short communication: CD3- CD56+ CD16+ natural killer cells and improvement of pregnancy outcome in IVF/ICSI failure after additional IVIG-Treatment. Am. J. Reprod. Immunol. 63:3 (2010), 263–265.
79. [79] Ramos‐Medina, R., García‐Segovia, A., Gil, J., Carbone, J., Aguarón de la Cruz, A., Seyfferth, A., Alonso, B., Alonso, J., León, J.A., Alecsandru, D., Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion. Am. J. Reprod. Immunol. 71:5 (2014), 458–466.
80. [80] Nydegger, U., Imbach, P., Hypothetic and Established Action Mechanisms of Therapy with Immunoglobulin G, Immunotherapy with Intravenous Immunoglobulins. 1991, Academic Press, New-York, 27–36.
81. [81] Chaouat, G., Lankar, D., Vaccination against spontaneous abortion in mice by preimmunization with an anti-diotypic antibody. Am. J. Reprod. Immunol. Microbiol. 16:4 (1988), 146–150.
82. [82] Brand, A., Witvliet, M., Claas, F., Eernisse, J., Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies. Br. J. Haematol. 69:4 (1988), 507–511.
83. [83] Carp, H.J., Sapir, T., Shoenfeld, Y., Intravenous immunoglobulin and recurrent pregnancy loss. Clin. Rev. Allergy Immunol. 29:3 (2005), 327–332.
84. [84] Ballow, M., The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127:2 (2011), 315–323.
85. [85] Omwandho, C.O., Gruessner, S.E., Roberts, T.K., Tinneberg, H.R., Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin. Chem. Lab. Med. 42:4 (2004), 359–370.
86. [86] Sewell, W., Jolles, S., Immunomodulatory action of intravenous immunoglobulin. J. Immunol. 107:4 (2002), 387–393.
87. [87] Moraru, M., Carbone, J., Alecsandru, D., Castillo-Rama, M., García-Segovia, A., Gil, J., Alonso, B., Aguarón, A., Ramos-Medina, R., Martínez de María, J., Intravenous immunoglobulin treatment increased live birth rate in a spanish cohort of women with recurrent reproductive failure and expanded CD56+ cells. Am. J. Reprod. Immunol. 68:1 (2012), 75–84.
88. [88] Kim, D.J., Lee, S.K., Kim, J.Y., Na, B.J., Hur, S.E., Lee, M., Kwak-Kim, J., Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3+ regulatory T cells in pregnant women with recurrent pregnancy loss. Am. J. Reprod. Immunol. 71:5 (2014), 441–450.
89. ®) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am. J. Reprod. Immunol. 61:2 (2009), 113–120.
90. [90] Thum, M.Y., Bhaskaran, S., Abdalla, H.I., Ford, B., Sumar, N., Bansal, A., Prednisolone suppresses NK cell cytotoxicity in vitro in women with a history of infertility and elevated NK cell cytotoxicity. Am. J. Reprod. Immunol. 59:3 (2008), 259–265.
91. [91] Rump, J., Schönborn, H., Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z. Rheumatol. 69:10 (2010), 903–909.
92. [92] Chambers, C.D., Johnson, D.L., Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy, Birth Defects Research Part A. Clin. Mol. Teratol. 94:8 (2012), 607–611.
93. [93] Osting, V.C., Carter, J.D., A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin. Drug Saf. 9:3 (2010), 421–429.
94. [94] Sills, E.S., Walsh, D.J., Shkrobot, L.V., Palermo, G.D., Walsh, A.P., Clinical experience with intravenous immunoglobulin and tnf-a inhibitor therapies for recurrent pregnancy loss. Ulster Med. J. 78:1 (2009), 57–58.
95. [95] Winger, E.E., Reed, J.L., Ashoush, S., El-Toukhy, T., Ahuja, S., Taranissi, M., Degree of TNF-α/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with adalimumab (Humira) and IVIG. Am. J. Reprod. Immunol. 65:6 (2011), 610–618.
96. [96] Sills, E., Perloe, M., Tucker, M.J., Kaplan, C.R., Palermo, G.D., Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am. J. Reprod. Immunol. 46:5 (2001), 366–368.
97. [97] Murashima, A., Treatment of patients with rheumatoid arthritis who desire to become pregnant–successful pregnancy in three cases treated with etanercept, Nihon rinsho. Jpn. J. Clin. Med. 66:11 (2008), 2215–2220.
98. [98] Berthelot, J.-M., De Bandt, M., Goupille, P., Solau-Gervais, E., Lioté, F., Goeb, V., Azaïs, I., Martin, A., Pallot-Prades, B., Maugars, Y., Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:1 (2009), 28–34.
99. ®) to treat immunologic-based infertility in IVF patients. Am. J. Reprod. Immunol. 66:3 (2011), 237–241.
100. [100] Gottsch, M.L., Van Kirk, E.A., Murdoch, W.J., Tumour necrosis factor alpha up-regulates matrix metalloproteinase-2 activity in periovulatory ovine follicles: metamorphic and endocrine implications. Reprod. Fertil. Dev. 12:2 (2000), 75–80.
101. [101] Murdoch, W.J., Proteolytic and cellular death mechanisms in ovulatory ovarian rupture. Neurosignals 9:2 (2000), 102–114.
102. [102] Sinha, A., Patient, C., Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept). J. Obstet. Gynaecol. 26:7 (2006), 689–691.
103. [103] Nagata, S., Tsuchiya, M., Asano, S., Kaziro, Y., Yamazaki, T., Yamamoto, O., Hirata, Y., Kubota, N., Oheda, M., Nomura, H., Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature, 1986, 415–418.
104. [104] Le Beau, M., Lemons, R.S., Carrino, J., Pettenati, M., Souza, L., Diaz, M., Rowley, J., Chromosomal localization of the human G-CSF gene to 17q11 proximal to the breakpoint of the t (15; 17) in acute promyelocytic leukemia. Leukemia 1:12 (1987), 795–799.
105. [105] Würfel, W., Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J. Reprod. Immunol. 108 (2015), 123–135.
106. [106] Scarpellini, F., Sbracia, M., Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum. Reprod. 24:11 (2009), 2703–2708.
107. [107] Duan, J.-S., Production of granulocyte colony stimulating factor in decidual tissue and its significance in pregnancy. Osaka City Med. J. 36:2 (1990), 81–97.
108. [108] Shorter, S., Vince, G., Starkey, P., Production of granulocyte colony-stimulating factor at the materno-foetal interface in human pregnancy. J. Immunol., 75(3), 1992, 468.
109. [109] Nicola, N., Metcalf, D., Binding of 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells. J. Cell. Physiol. 124:2 (1985), 313–321.
110. [110] Vandermolen, D.T., Gu, Y., Human endometrial expression of granulocyte colony-Stimulating factor (G-CSF) and its receptor, stimulation of endometrial G-CSF production by interleukin-1β, and G-CSF inhibition of choriocarcinoma cell proliferation. Am. J. Reprod. Immunol. 36:5 (1996), 278–284.
111. [111] Rapoport, A., Abboud, C., DiPersio, J., Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev. 6:1 (1992), 43–57.
112. [112] Shimoda, K., Feng, J., Murakami, H., Nagata, S., Watling, D., Rogers, N.C., Stark, G.R., Kerr, I.M., Ihle, J.N., Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. Blood 90:2 (1997), 597–604.
113. [113] Novales, J., Salva, A., Modanlou, H., Kaplan, D., Del Castillo, J., Andersen, J., Medlock, E., Maternal administration of granulocyte colony-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection. Blood 81:4 (1993), 923–927.
114. [114] Marino, V.J., Roguin, L.P., The granulocyte colony stimulating factor (G-CSF) activates Jak/STAT and MAPK pathways in a trophoblastic cell line. J. Cell. Biochem. 103:5 (2008), 1512–1523.
115. [115] Santjohanser, C., Knieper, C., Franz, C., Hirv, K., Meri, O., Schleyer, M., Würfel, W., Toth, B., Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. Arch. Immunol. Ther. Exp. 61:2 (2013), 159–164.
116. [116] Pan, L., Delmonte, J.J., Jalonen, C.K., Ferrara, J., Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:12 (1995), 4422–4429.
117. [117] Gleicher, N., Kim, A., Michaeli, T., Lee, H., Shohat-Tal, A., Lazzaroni, E., Barad, D., A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Hum. Reprod. 28:1 (2013), 172–177.
118. [118] Wicks, I.P., Roberts, A.W., Targeting GM-CSF in inflammatory diseases. Nat. Rev. Rheumatol. 12:1 (2016), 37–48.
119. [119] Zhao, Y., Chegini, N., Human fallopian tube expresses granulocyte-macrophage colony stimulating factor (GM-CSF) and GM-CSF alpha and beta receptors and contain immunoreactive GM-CSF protein. J. Clin. Endocrinol. Metab. 79:2 (1994), 662–665.
120. [120] Giacomini, G., Tabibzadeh, S., Satyaswaroop, P., Bonsi, L., Vitale, L., Bagnara, G., Strippoli, P., Jasonni, V., Epithelial cells are the major source of biologically active granulocyte macrophage colony-stimulating factor in human endometrium. Hum. Reprod. 10:12 (1995), 3259–3263.
121. [121] Zhao, Y., Chegini, N., The expression of granulocyte macrophage-colony stimulating factor (GM-CSF) and receptors in human endometrium. Am. J. Reprod. Immunol. 42:5 (1999), 303–311.
122. [122] Quelle, F.W., Sato, N., Witthuhn, B.A., Inhorn, R.C., Eder, M., Miyajima, A., Griffin, J.D., Ihle, J.N., JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol. Cell. Biol. 14:7 (1994), 4335–4341.
123. [123] Mui, A., Wakao, H., O'farrell, A., Harada, N., Miyajima, A., Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J., 14(6), 1995, 1166.
124. [124] Bhattacharya, P., Thiruppathi, M., Elshabrawy, H.A., Alharshawi, K., Kumar, P., Prabhakar, B.S., GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 75:2 (2015), 261–271.
125. [125] Ziebe, S., Loft, A., Povlsen, B.B., Erb, K., Agerholm, I., Aasted, M., Gabrielsen, A., Hnida, C., Zobel, D.P., Munding, B., A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in embryo culture medium for in vitro fertilization. Fertil. Steril., 99(6), 2013 (1600-1609e2).
126. [126] Perricone, R., De Carolis, C., Giacomelli, R., Guarino, M.D., De Sanctis, G., Fontana, L., GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. Am. J. Reprod. Immunol. 50:3 (2003), 232–237.
127. [128] Beer, A.E., Quebbeman, J.F., Ayers, J.W., Haines, R.F., Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans. Obstet. Gynecol. Surv. 37:7 (1982), 487–489.
128. [129] Taylor, C., Faulk, W.P., Prevention of recurrent abortion with leucocyte transfusions. Lancet 318:8237 (1981), 68–70.
129. [130] Kling, C., Steinmann, J., Westphal, E., Magez, J., Kabelitz, D., Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum. Reprod. 21:2 (2006), 429–435.
130. [131] Prigoshin, N., Tambutti, M., Redal, M., Gogorza, S., Lancuba, S., Nicholson, R., Testa, R., Microchimerism and blocking activity in women with recurrent spontaneous abortion (RSA) after alloimmunization with the partner's lymphocytes. J. Reprod. Immunol. 44:1 (1999), 41–54.
131. [132] Pandey, M.K., Thakur, S., Agrawal, S., Lymphocyte immunotherapy and its probable mechanism in the maintenance of pregnancy in women with recurrent spontaneous abortion. Arch. Gynecol. Obstet. 269:3 (2004), 161–172.
132. [133] Pandey, M.K., Saxena, V., Agrawal, S., Characterization of mixed lymphocyte reaction blocking antibodies (MLR-Bf) in human pregnancy. BMC Pregnancy Childbirth, 3(1), 2003, 1.
133. [134] Ito, K., Tanaka, T., Tsutsumi, N., Obata, F., Kashiwagi, N., Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptors. Hum. Reprod. 14:3 (1999), 650–655.
134. [135] Li, D., Li, C., Zhu, Y., Comparative study of the third party and paternal leukocyte immunization in recurrent spontaneous abortion of lowered maternal-fetal immuno-recognition. Zhonghua fu chan ke za zhi 33:10 (1998), 597–600.
135. [136] Orgad, S., Loewenthal, R., Gazit, E., Sadetzki, S., Novikov, I., Carp, H., The prognostic value of anti-paternal antibodies and leukocyte immunizations on the proportion of live births in couples with consecutive recurrent miscarriages. Hum. Reprod. 14:12 (1999), 2974–2979.
136. [137] Clark, D.A., Daya, S., Trials and tribulation in the treatment of recurrent spontaneous abortion. Am. J. Reprod. Immunol. 25:1 (1991), 18–24.
137. [138] Smith, J.B., Cowchock, F.S., Lata, J.A., Hankinson, B.T., The number of cells used for immunotherapy of repeated spontaneous abortion influences pregnancy outcome. J. Reprod. Immunol. 22:3 (1992), 217–224.
138. [139] Illeni, M.T., Marelli, G., Parazzini, F., Acaia, B., Bocciolone, L., Bontempelli, M., Faden, D., Fedele, L., Maffeis, A., Radici, E., Immunology: immunotherapy and recurrent abortion: a randomized clinical trial. Hum. Reprod. 9:7 (1994), 1247–1249.
139. [140] Matsubayashi, H., Izumi, S.I., Sugi, T., Yoshikata, K., Makino, T., Maruyama, T., Ozawa, N., Yoshimura, Y., Anti-paternal antibodies by flow cytometry in the management of alloimmunization on recurrent miscarriages. Am. J. Reprod. Immunol. 44:5 (2000), 284–288.
140. [141] Cowchock, F.S., Smith, J.B., Fertility among women with recurrent spontaneous abortions—the effect of paternal cell immunization treatment. Am. J. Reprod. Immunol. 33:2 (1995), 176–181.
141. [142] Maejima, M., Fujii, T., Yamashita, T., Hara, N., Hamai, Y., Miki, A., Kozuma, S., Okai, T., Shibata, Y., Taketani, Y., Immunotherapy before and during pregnancy improves pregnancy outcome in women who suffer from recurrent abortion and did not benefit from immunotherapy before pregnancy. Am. J. Reprod. Immunol. 39:1 (1998), 12–15.
142. [143] Christiansen, O.B., Mathiesen, O., Husth, M., Lauritsen, J.G., Grunnet, N., Placebo-controlled trial of active immunization with third party leukocytes in recurrent miscarriage. Acta Obstet. Gynecol. Scand. 73:3 (1994), 261–268.
143. [144] Ndukwe, G., Recurrent embryo implantation failure after in vitro fertilisation: improved outcome following intralipid infusion in women with elevated T Helper 1 response. Hum. Fertil. (Camb.) 14:2 (2011), 21–22.
144. [145] Driver, I., Feather, J., King, P., Dawson, J., The optical properties of aqueous suspensions of Intralipid, a fat emulsion. Phys. Med. Biol. 34:12 (1989), 1927–1930.
145. [146] Granato, D., Blum, S., Rössle, C., Le Boucher, J., Malnoë, A., Dutot, G., Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN J. Parenter. Enteral Nutr. 24:2 (2000), 113–118.
146. [147] Ota, D.M., Jessup, J.M., Babcock, G.F., Kirschbaum, L., Mountain, C.F., Mcmurtrey, M.J., Copeland, E.M., Immune function during intravenous administration of a soybean oil emulsion. JPEN J. Parenter. Enteral Nutr. 9:1 (1985), 23–27.
147. [148] Palmblad, J., Intravenous lipid emulsions and host defense—a critical review. Clin. Nutr. 10:6 (1991), 303–308.
148. [149] Calder, P., Sherrington, E., Askanazi, J., Newsholme, E., Inhibition of lymphocyte proliferation in vitro by two lipid emulsions with different fatty acid compositions. Clin. Nutr. 13:2 (1994), 69–74.
149. [150] Søyland, E., Nenseter, M., Braathen, L., Drevon, C., Very long chain n-3 and n-6 polyunsaturated fatty acids inhibit proliferation of human T-lymphocytes in vitro. Eur. J. Clin. Invest. 23:2 (1993), 112–121.
150. [151] Calder, P.C., Newsholme, E.A., Polyunsaturated fatty acids suppress human peripheral blood lymphocyte proliferation and interleukin-2 production. Clin. Sci. (London, England: 1979) 82:6 (1992), 695–700.
151. [152] Meydani, S.N., Endres, S., Woods, M.M., Goldin, B.R., Soo, C., Morrill-Labrode, A., Dinarello, C.A., Gorbach, S.L., Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121:4 (1991), 547–555.
152. [153] Calder, P.C., Bond, J.A., Bevan, S.J., Hunt, S.V., Newsholme, E.A., Effect of fatty acids on the proliferation of concanavalin A-stimulated rat lymph node lymphocytes. Int. J. Biochem. 23:5–6 (1991), 579–588.
153. [154] Calder, P.C., Yaqoob, P., Newsholme, E.A., Triacylglycerol metabolism by lymphocytes and the effect of triacylglycerols on lymphocyte proliferation. Biochem. J. 298:3 (1994), 605–611.
154. [155] Kinsella, J.E., Lokesh, B., Broughton, S., Whelan, J., Dietary polyunsaturated fatty acids and eicosanoids: potential effects on the modulation of inflammatory and immune cells: an overview. Nutrition (Burbank) 6:1 (1990), 24–44.
155. [156] Gogos, C.A., Kalfarentzos, F., Total parenteral nutrition and immune system activity: a review. Nutrition (Burbank, Los Angeles County Calif.) 11:4 (1994), 339–344.
156. [157] Kohelet, D., Peller, S., Arbel, E., Goldberg, M., Preincubation with intravenous lipid emulsion reduces chemotactic motility of neutrophils in cord blood. JPEN J. Parenter. Enteral Nutr. 14:5 (1990), 472–473.
157. [158] Gogos, C.A., Zoumbos, N., Makri, M., Kalfarentzos, F., Medium-and long-chain triglycerides have different effects on the synthesis of tumor necrosis factor by human mononuclear cells in patients under total parenteral nutrition. J. Am. Coll. Nutr. 13:1 (1994), 40–44.
158. [159] Clark, D.A., Intralipid as treatment for recurrent unexplained abortion?. Am. J. Reprod. Immunol. 32:4 (1994), 290–293.